RESTRUCTURING AND INTEGRATION (Details 3) (USD $)	3 Months Ended	12 Months Ended					1 Months Ended			12 Months Ended			12 Months Ended					1 Months Ended	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2011	Dec. 31, 2010	Dec. 31, 2011 Pre merger total rationalization cost	Dec. 31, 2010 Pre merger total rationalization cost	Dec. 31, 2009 Pre merger total rationalization cost	Jan. 31, 2010 Manufacturing Operations Sale of manufacturing facility at Dorado	Sep. 30, 2010 Manufacturing Operations Manufacturing facility at Carolina	Jul. 31, 2010 Pharmaceutical Sciences Operations Manufacturing facility at Carolina	Dec. 31, 2010 Pharmaceutical Sciences Operations Sale of CRD	Dec. 31, 2009 Pharmaceutical Sciences Operations Sale of CRD	Jul. 31, 2010 Pharmaceutical Sciences Operations Sale of CRD	Dec. 31, 2009 Pharmaceutical Sciences Operations Research and development facility at Ontario employee	Dec. 31, 2009 Pharmaceutical Sciences Operations Research and development facility at Ontario Equipment and leasehold improvements	Dec. 31, 2009 Pharmaceutical Sciences Operations Research and development facility at Virginia location	Dec. 31, 2009 Pharmaceutical Sciences Operations Research and development facility at Virginia Leasehold improvements	Dec. 31, 2009 Pharmaceutical Sciences Operations Sale of research and development facility at Dublin	Nov. 30, 2009 Corporate	Dec. 31, 2010 Asset Impairments Manufacturing Operations Pre merger total rationalization cost	Dec. 31, 2009 Asset Impairments Manufacturing Operations Pre merger total rationalization cost	Dec. 31, 2009 Asset Impairments Pharmaceutical Sciences Operations Pre merger total rationalization cost	Dec. 31, 2009 Asset Impairments Corporate Pre merger total rationalization cost	Dec. 31, 2010 Employee Termination Costs Manufacturing Operations Pre merger total rationalization cost	Dec. 31, 2009 Employee Termination Costs Manufacturing Operations Pre merger total rationalization cost	Dec. 31, 2010 Employee Termination Costs Pharmaceutical Sciences Operations Pre merger total rationalization cost	Dec. 31, 2009 Employee Termination Costs Pharmaceutical Sciences Operations Pre merger total rationalization cost	Dec. 31, 2010 Employee Termination Costs Pharmaceutical Sciences Operations Sale of CRD employee	Dec. 31, 2011 Employee Termination Costs - Severance and Related Benefits	Dec. 31, 2010 Employee Termination Costs - Severance and Related Benefits	Dec. 31, 2010 Employee Termination Costs - Severance and Related Benefits Manufacturing Operations employee	Dec. 31, 2009 Employee Termination Costs - Severance and Related Benefits Pharmaceutical Sciences Operations Research and development facility at Ontario	Dec. 31, 2011 Contract Termination, Facility Closure and Other Costs	Dec. 31, 2010 Contract Termination, Facility Closure and Other Costs	Dec. 31, 2011 Contract Termination, Facility Closure and Other Costs Pre merger total rationalization cost	Dec. 31, 2010 Contract Termination, Facility Closure and Other Costs Pre merger total rationalization cost	Dec. 31, 2009 Contract Termination, Facility Closure and Other Costs Pre merger total rationalization cost	Dec. 31, 2011 Lease termination	Dec. 31, 2009 Lease termination Pharmaceutical Sciences Operations Research and development facility at Virginia
Restructuring reserve
Balance at the beginning of the period		$ 26,459,000		$ 3,680,000	$ 10,776,000	$ 6,655,000																	$ 6,210,000	$ 3,309,000	$ 234,000			$ 24,789,000				$ 1,670,000		$ 3,680,000	$ 4,332,000	$ 3,346,000
Costs incurred and charged to expense		46,941,000	134,821,000	(356,000)	6,019,000	30,033,000													400,000	7,591,000	2,784,000	10,968,000	1,330,000	4,942,000	1,924,000	1,441,000		14,548,000	58,727,000			28,938,000	12,862,000	(356,000)	2,365,000	2,307,000	1,400,000	1,400,000
Cash payments		(55,582,000)	(56,443,000)	(1,078,000)	(12,614,000)	(4,640,000)																	(7,540,000)	(2,041,000)	(2,057,000)	(1,278,000)		(38,168,000)	(33,938,000)			(15,381,000)	(8,755,000)	(1,078,000)	(3,017,000)	(1,321,000)
Non-cash adjustments		(4,665,000)	(51,919,000)	(2,246,000)	(501,000)	(21,272,000)													(400,000)	(7,591,000)	(2,784,000)	(10,968,000)			(101,000)	71,000		989,000				(4,913,000)	(2,437,000)	(2,246,000)
Balance at the end of the period	26,459,000	13,153,000	26,459,000		3,680,000	10,776,000																		6,210,000		234,000		2,158,000	24,789,000			10,314,000	1,670,000		3,680,000	4,332,000
Net cash proceeds							8,500,000		6,400,000								5,200,000
Impairment charges														500,000			9,900,000
Impairment charges relating to disposal group not including discontinued operation								400,000
Employee termination costs																											1,900,000			9,600,000	1,400,000
Number of employees terminated													50														70			240
Disposal group including discontinued operation, Balance sheet disclosures
Net assets and liabilities of disposal group, Current												1,600,000
Property, plant and equipment, net												4,800,000
Disposal group including discontinued operation, Income statement disclosures
Service and other revenues										5,642,000	12,027,000
Cost of services										7,211,000	13,849,000
Selling, general and administrative expenses										2,328,000	3,718,000
Total operating expenses										9,539,000	17,567,000
Operating loss										(3,897,000)	(5,540,000)
Internal and external costs incurred	5,300,000							1,300,000
Foreign exchange gain (loss)										(102,000)	93,000
Net loss										(3,999,000)	(5,447,000)
Accelerated depreciation expense																1,600,000
Number of locations closed															1
Net proceeds from sale and leaseback																		17,800,000
Loss on disposal of corporate headquarters																		11,000,000
Minimum future rental payments		$ 70,747,000